UNSPSC 51282808: Metronidazole

This classification denotes a trichomonacide agent and protein synthesis inhibitor with the molecular formula C6H9N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140QMO216E, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro- but generally known as metronidazole, which bears US NIH Compound Identifier 4173. European Medicines Agency schedules Metronidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08922MIG. The term METRONIDAZOLE is an International Non-Proprietary Name.

UNSPSC 51282808 Metronidazole is a Commodity code that captures individual pharmaceutical products purchased by state and local health agencies, but recent state and local opportunities show minimal direct activity under this specific drug code—the source contains no solicitations explicitly seeking metronidazole. Instead, state and local buyers are procuring metronidazole as part of broader medical supply, pharmacy benefit, and generic pharmaceutical contracts. The City of Tampa's IFB for medical and first aid supplies to the Tampa Fire Department Rescue Division includes 169 line items of emergency medical consumables such as respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, and bandaging materials. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has issued an RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, requiring manufacturers to provide comprehensive pricing and compliance with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission posted an RFI exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. These procurements show that state and local buyers acquire individual pharmaceuticals through cooperative purchasing vehicles, direct manufacturer contracts, and emergency medical supply frameworks rather than as standalone drug line items.

Solicitation activity appears concentrated in the Southeast and Upper Midwest. Tampa's medical supply bid (IFB, due March 13, 2026, estimated at $700,000) explicitly serves the local fire department and is sheltered for certified Small Local Business Enterprises with a 5 percent bid discount. MMCAP's pharmaceutical RFP (due March 26, 2026) spans Minnesota and Oregon through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026. Seminole County, Florida sought naloxone and drug deactivation systems through an IFB (due July 26, 2023—note: this opportunity is substantially past-dated and the due-date discrepancy suggests stale data in the source). The Texas HHS RFI (April 3, 2026) represents exploratory market research rather than a formal solicitation. Geographic spread is limited, and no single jurisdiction emerges as a standout repeat buyer under the metronidazole code specifically.